查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963987

基因静默市场－全球产业规模、份额、趋势、机会、预测：按产品/服务、应用、地区和竞争格局划分，2021-2031年

Gene Silencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球基因静默市场预计将从 2025 年的 29.1 亿美元成长到 2031 年的 44.8 亿美元，复合年增长率为 7.46%。

此治疗领域专注于精准抑制特定的致病基因，主要透过反义寡核苷酸和RNA干扰等机制来实现。市场成长的根本驱动力在于肿瘤和慢性遗传疾病的日益普遍，这些疾病需要标靶分子干预，以及脂质奈米颗粒递送技术的显着进步。根据美国基因与细胞治疗学会（ASGCT）预测，到2025年，该产业将呈现强劲的发展势头，仅第二季就启动了38项针对RNA疗法的新临床试验，就足以证明这一点。

市场概览
预测期 2027-2031
市场规模：2025年 29.1亿美元
市场规模：2031年 44.8亿美元
复合年增长率：2026-2031年 7.46%
成长最快的细分市场 RNAi
最大的市场 北美洲

儘管取得了这些进展，但基因定序剂的稳定性和细胞内递送仍面临许多挑战。 RNA分子在血液中的生理性降解，以及如何在不引起脱靶毒性的情况下将大分子转运穿过细胞膜，仍然是主要的障碍。这些技术难题持续阻碍基因沉默治疗方法的广泛商业化和临床应用，也是限制基因静默疗法普及的主要障碍。

市场驱动因素

监管核准的加速和临床研发管线的持续拓展是全球基因静默市场的主要驱动力，推动该领域从实验研究走向具体的商业性化应用。随着监管机构确认反义寡核苷酸和RNA干扰疗法的安全性，针对未被满足的医疗需求（尤其是在罕见遗传疾病领域）的新型治疗方法正加速进入市场。根据BioPharma PEG报道，2024年12月，FDA核准了TringolzaFirst-in-Class用于治疗遗传性乳糜微粒血症的RNA标靶治疗。该领域的经济可行性也得益于其商业性扩充性。例如，根据Alnilam Pharmaceuticals公司公布的2025年第三季净产品销售额达到8.51亿美元，年增103%。这凸显了市场对有效基因静默疗法的强劲需求。

同时，随着领先的製药公司努力克服持续存在的细胞内递送难题，策略联盟和合作正在重塑市场动态。产业领导者正收购专业的生物技术公司，以即时获得能够针对肝臟以外肌肉组织的独特递送平台，例如抗体-寡核苷酸偶联物。诺华公司于2025年10月宣布以约120亿美元收购Avidity Biosciences，以获得先进的RNA架构，这就是高价值整合趋势的一个例证。这些资本密集型合作提供了必要的资金，以推动复杂的临床试验，加速下一代治疗方法的开发，并确保永续的长期市场扩张。

市场挑战

基因静默剂的稳定性和细胞内递送持续存在的挑战是限制全球基因静默市场扩张的一大瓶颈。儘管RNA疗法具有巨大的治疗潜力，但将大分子无毒无害地穿过细胞膜的技术难题常常导致临床试验失败。这些递送障碍增加了研发项目的风险，造成后期临床试验的高脱落率，并使监管核准之路更加复杂。因此，商业化进程被显着延长，从而延缓了潜在根治性治疗方法进入医疗体系的时间。

这种高风险环境将直接影响市场成长所需的金融生态系统，因为投资者对面临这些尚未解决的技术挑战的早期新创公司将更加谨慎。基础研究经费的减少将阻碍候选药物转化为商业性化治疗方法的进程。根据美国基因与细胞治疗学会（ASGCT）预测，2025年第二季Start-Ups的资金筹措仅1.97亿美元，反映出该领域投资的持续下降。资金的大幅减少将削弱产业的创新能力，进而阻碍整体市场成长。

市场趋势

RNA生物农药和作物保护技术的兴起，代表着农业领域的变革性市场扩张，它将基因静默原理应用于永续的害虫管理。与频谱化学药剂不同，这些可生物降解的解决方案利用双链RNA选择性地沉默特定农业害虫的关键基因，从而在保护益虫的同时，最大限度地减少对环境的毒性。 2025年10月，Greenlight Biosciences公司获得了美国环保署（EPA）颁发的「Noroa」註册证书，标誌着这项商业性突破的实现。 Noroa是一种新型的RNA解决方案，专门用于控制和标靶化蜜蜂蜂群中的瓦螨。

同时，表观遗传和转录基因静默技术的出现正在建立一种新的治疗范式，该范式能够在不改变DNA序列的情况下实现持续的基因抑制。这种方法利用表观遗传编辑技术来调控甲基化模式等化学标记，从而在转录层面上有效地使疾病相关基因惰性，同时避免了双股DNA断裂带来的安全风险。投资界也认识到了这种方法的潜力；例如，Epigenic Therapeutics公司于2025年9月完成了6,000万美元的B轮资金筹措，以加速其专有基因调控平台的临床开发。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球基因静默市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品/服务分类（RNAi、CRISPR-Cas9、反义寡核苷酸、其他）
    • 依应用领域（神经学、肿瘤学、感染疾病、代谢性疾病、药物製造等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美基因静默市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲基因静默市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区基因静默市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲基因静默市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲基因静默市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球基因静默市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Revvity, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 28069

The Global Gene Silencing Market is projected to expand from USD 2.91 Billion in 2025 to USD 4.48 Billion by 2031, reflecting a compound annual growth rate of 7.46%. This therapeutic field focuses on the precise downregulation of specific disease-causing genes, predominantly employing mechanisms such as antisense oligonucleotides and RNA interference. The market's growth is fundamentally fueled by the increasing prevalence of oncological conditions and chronic genetic disorders that require targeted molecular interventions, alongside significant progress in lipid nanoparticle delivery technologies. According to the 'American Society of Gene & Cell Therapy', the industry saw strong developmental momentum in '2025', evidenced by the initiation of 38 new clinical trials dedicated to RNA therapies during the second quarter alone.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.91 Billion
Market Size 2031USD 4.48 Billion
CAGR 2026-20317.46%
Fastest Growing SegmentRNAi
Largest MarketNorth America

Despite these advancements, the sector encounters substantial hurdles regarding the stability and intracellular delivery of silencing agents. The physiological degradation of RNA molecules within the bloodstream, combined with the challenge of transporting large macromolecules across cellular membranes without causing off-target toxicity, remains a critical obstacle. These technical difficulties continue to impede the broad commercialization and clinical efficacy of these therapies, representing major barriers that limit the widespread adoption of gene silencing treatments.

Market Driver

Accelerated regulatory approvals and expanding clinical pipelines act as the primary catalyst for the Global Gene Silencing Market, shifting the sector from experimental research to tangible commercial realization. As regulatory agencies confirm the safety profiles of antisense and RNA interference modalities, the market entry of novel therapies has quickened, specifically addressing unmet needs in rare genetic diseases. This momentum was evident when, according to Biopharma PEG, the FDA approved Tryngolza in December 2024, a first-in-class RNA-targeted medicine for familial chylomicronemia syndrome. The financial viability of the sector is further validated by commercial scalability; for instance, according to Alnylam Pharmaceuticals, the company reported third-quarter net product revenues of $851 million in October 2025, marking a 103% year-over-year increase that underscores the strong demand for effective gene silencing interventions.

Concurrently, strategic partnerships and collaborations are reshaping market dynamics as major pharmaceutical companies strive to overcome persistent intracellular delivery challenges. By acquiring specialized biotechnology firms, industry leaders gain immediate access to proprietary delivery platforms-such as antibody oligonucleotide conjugates-that can target tissues like muscle beyond the liver. This trend of high-value consolidation is exemplified by Novartis, which, according to reports in October 2025, agreed to acquire Avidity Biosciences for approximately $12 billion to secure its advanced RNA architecture. These capital-intensive collaborations provide the necessary funding to navigate complex clinical trials and accelerate the development of next-generation modalities, ensuring sustainable long-term market expansion.

Market Challenge

The persistent difficulty regarding the stability and intracellular delivery of silencing agents acts as a critical bottleneck restricting the expansion of the Global Gene Silencing Market. Although RNA therapies offer significant therapeutic promise, the technical inability to transport large macromolecules across cellular membranes without toxicity or degradation frequently results in clinical failures. These delivery barriers increase the risk profile of developmental programs, leading to significant attrition in late-stage trials and complicating the path to regulatory approval. Consequently, the timeline for commercialization is significantly prolonged, delaying the entry of potentially curative treatments into the healthcare system.

This high-risk environment directly impacts the financial ecosystem required for market growth, as investors exercise greater caution toward early-stage ventures grappling with these unresolved technical hurdles. A contraction in available capital for foundational research stalls the progression of pipeline candidates into commercially viable treatments. According to the 'American Society of Gene & Cell Therapy', in '2025', start-up financings raised only $197 million in the second quarter, reflecting a continued decline in investment volume for the sector. This reduction in essential funding impedes the industry's ability to innovate, thereby hampering the overall trajectory of the market.

Market Trends

The rise of RNA-based biopesticides and crop protection in agriculture signifies a transformative expansion of the market, applying gene silencing principles to sustainable pest management. Unlike broad-spectrum chemical agents, these biodegradable solutions employ double-stranded RNA to selectively silence essential genes in specific agricultural pests, thereby minimizing environmental toxicity and preserving beneficial insects. This commercial breakthrough was highlighted when, according to GreenLight Biosciences, the company received registration from the U.S. Environmental Protection Agency in October 2025 for Norroa, a novel RNA-based solution specifically designed to control and target Varroa mites in honeybee colonies.

Simultaneously, the emergence of epigenetic and transcriptional gene silencing is establishing a new therapeutic paradigm that achieves durable gene repression without altering the underlying DNA sequence. This approach leverages epigenetic editors to modulate chemical markers, such as methylation patterns, effectively turning off disease-associated genes at the transcriptional level while avoiding the safety risks associated with double-strand DNA breaks. The investment community has recognized the potential of this modality; for instance, according to Epigenic Therapeutics, in September 2025, the company completed a $60 million Series B financing round to accelerate the clinical development of its proprietary gene modulation platform.

Key Market Players

  • Revvity, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Silencing Market, By Product & Service

  • RNAi
  • CRISPR-Cas9
  • Antisense Oligonucleotides
  • Others

Gene Silencing Market, By Application

  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Therapeutics Manufacturing
  • Others

Gene Silencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customizations:

Global Gene Silencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Silencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others)
    • 5.2.2. By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Gene Silencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Silencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Gene Silencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Gene Silencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Application

7. Europe Gene Silencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Silencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Application
    • 7.3.2. France Gene Silencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Gene Silencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Gene Silencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Gene Silencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Application

8. Asia Pacific Gene Silencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Silencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Application
    • 8.3.2. India Gene Silencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Gene Silencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Gene Silencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Gene Silencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Application

9. Middle East & Africa Gene Silencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Silencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Gene Silencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Gene Silencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Application

10. South America Gene Silencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Silencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Gene Silencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Gene Silencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Silencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Revvity, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Danaher Corporation
  • 15.3. Agilent Technologies, Inc.
  • 15.4. GenScript Biotech Corporation
  • 15.5. Merck KGaA
  • 15.6. Thermo Fisher Scientific, Inc.
  • 15.7. Illumina, Inc.
  • 15.8. Bio-Rad Laboratories, Inc.
  • 15.9. Bio-Techne Corporation
  • 15.10. New England Biolabs, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer